FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT
Department of endocrinologySlužba endokrinologije, Clinic for internal medicine, Clinical Hospital Center Zemun , Belgrade , Serbia
Faculty of Medicine, University of Belgrade , Belgrade , Serbia
Department of gastroenterology with hepatology, Clinic for internal medicine, Clinical Hospital Center Zemun , Belgrade , Serbia
Faculty of Medicine, University of Belgrade , Belgrade , Serbia
Department of endocrinology, Clinic for internal medicine, Clinical Hospital Center Zemun Belgrade , Belgrade , Serbia
Faculty of Medicine, University of Belgrade , Belgrade , Serbia
Volume 40, Issue 1 (2026)
Abstract
Introduction. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease nowadays which has contributed to significant cardiovascular and hepatic morbidity and mortality. Recognizing the metabolic concept resulted in an evolution in disease nomenclature, as well as the development of innovative treatments for MASLD, the hepatic manifestation of metabolic syndrome.
Objective. To present contemporary trends in the management of MASLD.
Methods. For the search methodology, we used the PubMed database. We employed the following keywords to search for original articles, reviews, and clinical guidelines from 2018. to 2025. year, such as „NAFLD/MASLD“, „NAFLD/MASLD biomarkers“, „NAFLD/MASLD diagnostic scores“, „NAFLD/MASLD innovative therapy“. We used original articles and reviews written in English, Serbian and Balkan-familiar languages. Special attention was given to the FIB-4 algorithm, newly developed non-invasive scores (SAFE, LiverRisk, MAFS), and biomarkers (MDA, 8-OHdG, CK-18, PRO-C3).
Results. MASLD has been associated to an increased risk of liver fibrosis and cirrhosis, hepatocellular carcinoma (HCC), and cardiovascular diseases. Emerging biomarkers enable early and accurate diagnosis and monitoring of treatment response, while innovative treatments including PPAR agonists, GLP-1 receptor agonists, and Resmetirom are mapping the personalized MASLD treatment.
Conclusion. MASLD is a chronic systemic disease requiring a multidisciplinary approach. Proper diagnosis and personalized innovative therapy create the favorable conditions for reducing cardiovascular and hepatic morbidity and mortality.
Keywords
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
